Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aclaris Therapeutics Inc. (ACRS:NASDAQ), powered by AI.
Aclaris Therapeutics Inc. is currently trading at $4.34. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aclaris Therapeutics Inc. on Alpha Lenz.
View Aclaris Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Aclaris Therapeutics Inc.'s ROE is -50.2%. Explore profitability and growth together.”
Ask for details →Aclaris Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in dermatology, immunology, and neurology. The company's primary objective is to discover and develop novel drug candidates that can be game-changers in treating conditions with limited treatment options. Notable for its pipeline of compounds targeting immuno-inflammatory regulatory mechanisms, Aclaris aims to bring new solutions to chronic skin conditions like psoriasis and vitiligo, as well as broader autoimmune disorders. The company's expertise in utilizing scientific advances complements its dedication to delivering effective treatments through rigorous clinical studies. Aclaris plays a significant role in the pharmaceutical landscape, contributing towards expanding therapeutic options in specialized medical fields, thereby potentially improving quality of life for patients worldwide. Its innovative approach and commitment to furthering medical research solidify its position as a pioneering entity within the biotech industry.
“Aclaris Therapeutics Inc.'s ROE is -50.2%. Explore profitability and growth together.”
Ask for details →Aclaris Therapeutics Inc. (ticker: ACRS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 61 employees.
The current price is $4.34 with a P/E ratio of -x and P/B of -x.
ROE is -50.20% and operating margin is -897.78%. Annual revenue is $8M.